BRAF and malignant colon neoplasm: We also confirm the synergistic activity of BRAF and EGFR inhibitors in BRAF-mutant colon cancer cell lines (Fig 4) [29, 30].The claim that EGFR and BRAF inhibitors are inactive in BRAF-mutant colon cancer lines appears unfounded however [29, 30], as we observed a clear IC50 response (Fig 4).